“Doctor, can this condition be completely cured?” I have heard countless patients ask this question. Yet before answering, I must first clarify one core point: what exactly does “cured” mean to them.

A 35-year-old female patient came to my outpatient clinic last week, diagnosed with a 1.2 cm prolactin-secreting pituitary microadenoma.

The first words she uttered after sitting down were: “Doctor, can this tumor be completely cured?”

I have encountered numerous patients posing the same question. But before responding, I always need to figure out one thing: the definition of “cured” in her mind.

The Vast Majority of Pituitary Adenomas Are Benign

This feature distinguishes them fundamentally from gliomas. Gliomas include high-grade subtypes that infiltrate aggressively, a trait rarely seen in pituitary adenomas. Pituitary tumors grow slowly and compress adjacent anatomical structures, yet they seldom invade intact cerebral parenchyma like malignant neoplasms.

Biologically speaking, they therefore possess the inherent basis for achieving cure.

That said, cure and permanent eradication are two distinct concepts. A cure is defined as complete surgical resection with no residual lesion visible on postoperative contrast-enhanced MRI, normalized hormone levels, and no tumor regrowth over years of follow-up. This therapeutic goal is readily achievable for pituitary adenomas.

Permanent eradication means the tumor will never recur. No neurosurgeon can guarantee this outcome for any type of tumor. Literature reports pituitary adenoma recurrence rates ranging from 5% to 20%, contingent on tumor subtype, size, and extent of surgical resection.

What Constitutes Complete Resection?

Transsphenoidal endoscopic surgery represents the mainstream surgical approach at present. Simply put, the surgeon accesses the sphenoid sinus through the nostrils to reach the sellar region and resect the adenoma. The procedure avoids craniotomy and leaves cerebral tissue untouched.

Contrast-enhanced MRI performed 3 to 6 months postoperatively without abnormal enhancing signals at the original tumor site generally confirms gross total resection.

I have performed many such operations. Microadenomas (less than 1 cm in diameter) carry a relatively high gross total resection rate. Smaller, well-circumscribed tumors are far easier to remove entirely. Macroadenomas present greater challenges: some grow large enough to compress the optic chiasm and impair vision, while others invade the cavernous sinus and encase the internal carotid artery. In such cases, achieving 100% complete resection is extremely difficult. Surgeons must strike a balance between maximal tumor removal and preservation of vital blood vessels and cranial nerves. Any unresectable residual tissue may require adjuvant radiotherapy or medical therapy for long-term control.

A critical statement from your reference materials rings true: “Surgery is a pivotal treatment milestone.” The extent of surgical resection directly determines the feasibility of subsequent management.

Can Medical Treatment Be Regarded as a Cure?

The answer varies by tumor subtype. Prolactin-secreting pituitary adenomas are characteristically sensitive to dopamine receptor agonists, including bromocriptine and cabergoline. For many patients with microadenomas, oral medication induces tumor shrinkage and normalized prolactin levels, yielding therapeutic effects comparable to surgery.

For these patients, pharmacotherapy itself constitutes a viable pathway toward cure, eliminating the need for surgical intervention.

However, long-term medication is mandatory, and hormone levels may rebound upon drug discontinuation. Patients who refuse lifelong oral therapy or fail to achieve satisfactory tumor shrinkage with medication remain candidates for surgery.

1. Is Postoperative Rehabilitation Required?

Your reference notes: “Rehabilitation therapy is unnecessary in patients without visual acuity or visual field defects.” This statement holds broadly true, yet I elaborate further for my patients.

Postoperative recovery of pituitary adenomas hinges on two key systems: visual function and endocrine function.

2, Visual function recovery

If the tumor compressed the optic chiasm preoperatively, resulting in blurred vision and visual field defects (the most typical presentation being bitemporal hemianopia, or loss of lateral visual fields in both eyes), surgical decompression allows the optic nerve time to repair itself. Some patients recover within several weeks, others require months, and a small minority experience incomplete recovery. No specialized rehabilitation training is needed during this period; only regular follow-up to grant the optic nerve sufficient healing time.

Endocrine function recovery

The pituitary gland acts as the central endocrine regulatory hub of the human body, and surgical manipulation inevitably impairs its function to varying degrees. Some patients develop postoperative complications including diabetes insipidus (excessive urine output and unrelenting thirst), hypocortisolism, and hypothyroidism. Most abnormalities are transient, with pituitary function spontaneously recovering within months; a small subset of patients requires long-term hormone replacement. This is not classified as rehabilitation therapy but endocrine replacement therapy: deficient hormones are supplemented, with dosage adjusted via regular blood tests.

To summarize precisely: patients with intact preoperative vision and normal postoperative endocrine assessment may resume daily life and work within a few days after surgery, with no additional rehabilitation required.

Regarding Tumor Recurrence

This is the topic patients least wish to hear, yet one I must address frankly.

Even following gross total resection, pituitary adenomas retain a risk of recurrence. I recommend an identical follow-up schedule for all postoperative patients: contrast-enhanced MRI plus full hormonal panel testing at 3 months postoperatively, then at 6 months, and annually thereafter with gradually lengthened intervals. Surveillance is more frequent within the first three years, and may be relaxed once disease stability is confirmed.

Recurrence does not equate to a hopeless prognosis. The vast majority of recurrent pituitary adenomas remain benign, with multiple effective control modalities available: repeat surgery, optimized medical regimens, or adjuvant radiotherapy.

One patient from last year underwent transsphenoidal surgery in 2019 with confirmed gross total resection, and four consecutive years of follow-up showed no abnormalities. During her fifth-year scan, a small 3–4 mm enhancing lesion was detected in the sellar region, triggering severe anxiety. We adjusted her medication regimen, and her disease remains well-controlled to this day; she continues working and caring for her family as normal.

Early detection greatly simplifies subsequent management.

Returning to the 35-year-old female patient mentioned at the start: she presented with a small prolactin microadenoma, and I offered her two treatment options: initial medical therapy, or transsphenoidal surgery if she preferred to avoid long-term medication. Both approaches carry favorable prospects for cure.

She opted to start drug treatment first. Three months later, she returned for reexamination: the tumor had shrunk by half, and her prolactin levels had normalized.

As she left the clinic after registration, she said to me: “If I had known it was not that serious, I would not have worried for months.”

Indeed, for pituitary adenoma patients, the disease itself is rarely truly frightening; the greatest distress stems from unfounded anxiety before understanding the condition.